Document Detail

Therapeutic strategies for the treatment of neuroblastoma.
MedLine Citation:
PMID:  16370386     Owner:  NLM     Status:  MEDLINE    
Neuroblastoma, the most common extracranial solid tumor in children, has a highly heterogeneous clinical presentation and course. Current risk-based therapy is usually effective in patients who have intermediate risk features, however, intensive treatment of advanced neuroblastoma in children over two years of age is far from satisfactory. Current therapeutic approaches include the optimization of pharmacokinetic and pharmacodynamic properties of conventional agents, as well as the development of novel targeted drugs, such as signal transduction and angiogenesis inhibitors, apoptosis/differentiation stimulators and immunotherapeutics. This review provides an overview of current treatment options and future perspectives for the therapy and prevention of neuroblastoma.
Elzbieta Izbicka; Tadeusz Izbicki
Related Documents :
17635006 - Self and proxy-reported health status and health-related quality of life in survivors o...
9302376 - Endocrine outcome in long-term survivors of low-grade hypothalamic/chiasmatic glioma.
18985676 - Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report fr...
7728576 - Complete surgical resection combined with aggressive adjuvant chemotherapy and bone mar...
23658746 - Associations of pon1 and genetic ancestry with obesity in early childhood.
16045986 - Health effects in children aged 3-6 years induced by environmental lead exposure.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in investigational drugs (London, England : 2000)     Volume:  6     ISSN:  1472-4472     ISO Abbreviation:  Curr Opin Investig Drugs     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2005-12-22     Completed Date:  2006-06-19     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100965718     Medline TA:  Curr Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  1200-14     Citation Subset:  IM    
Institute for Drug Development, Cancer Therapy and Research Center, 14960 Omicron Drive, San Antonio, TX 78245, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Angiogenesis Inhibitors / administration & dosage*,  therapeutic use
Antineoplastic Agents / administration & dosage*,  therapeutic use
Apoptosis / drug effects
Cancer Vaccines / administration & dosage*
Cell Differentiation / drug effects
Cell Proliferation / drug effects
Drug Combinations
Drug Delivery Systems*
Drug Design
Drug Resistance, Neoplasm
Drug Therapy, Combination
Neuroblastoma / drug therapy*,  genetics,  immunology
Nuclear Proteins / genetics,  metabolism
Oncogene Proteins / genetics,  metabolism
Randomized Controlled Trials as Topic
Signal Transduction / drug effects
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antineoplastic Agents; 0/Cancer Vaccines; 0/Drug Combinations; 0/MYCN protein, human; 0/Nuclear Proteins; 0/Oncogene Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Technology evaluation: denosumab, Amgen.
Next Document:  Potential role of the antiproliferative cytokine beta-galactoside binding protein in cancer therapy.